Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,888 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.
Chimalakonda A, Singhal S, Darbenzio R, Dockens R, Marchisin D, Banerjee S, Girgis IG, Throup J, He B, Aras U, Murthy B. Chimalakonda A, et al. Among authors: singhal s. Clin Pharmacol Drug Dev. 2022 Apr;11(4):442-453. doi: 10.1002/cpdd.1056. Epub 2022 Feb 19. Clin Pharmacol Drug Dev. 2022. PMID: 35182043 Free PMC article. Clinical Trial.
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand E, et al. Among authors: singhal s. Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369798 Free PMC article. Clinical Trial.
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Morand EF, Pike M, Merrill J, F van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand EF, et al. Among authors: singhal s. Expert Opin Investig Drugs. 2024 May;33(5):431-440. doi: 10.1080/13543784.2024.2337736. Epub 2024 May 29. Expert Opin Investig Drugs. 2024. PMID: 38807572
Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
Bihorel S, Singhal S, Shevell D, Sun H, Xie J, Basdeo S, Liu A, Dutta S, Ludwig E, Huang H, Lin KJ, Fura A, Throup J, Girgis IG. Bihorel S, et al. Among authors: singhal s. Clin Pharmacol Drug Dev. 2021 Jan;10(1):8-21. doi: 10.1002/cpdd.878. Epub 2020 Oct 8. Clin Pharmacol Drug Dev. 2021. PMID: 33090733 Free PMC article. Clinical Trial.
1,888 results